{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-005220","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.762006+00:00","generated_at":"2026-06-18T14:45:18.657253+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Puma Biotech Q4 net loss $5.6M; FY net income $0; guides FY2023 product rev $205-210M","bullets":["Q4 product revenue $53.7M (+5% YoY); full year $200.0M (+6% YoY).","Q4 GAAP net loss $5.6M ($0.12/sh) vs net income $4.2M in Q4 2021; includes $12.4M legal accrual.","Full year 2022 GAAP net income $0.0M ($0.00/sh) vs net loss $29.1M in 2021.","Non-GAAP adjusted net income FY2022 $11.8M ($0.26/sh) vs $3.5M ($0.09/sh) in 2021.","FY2023 guidance: product revenue $205-210M, royalty rev $25-30M, net income $20-24M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-005220","json":"https://secwatch.observer/filing/0001437749-23-005220.json","markdown":"https://secwatch.observer/filing/0001437749-23-005220.md","text":"https://secwatch.observer/filing/0001437749-23-005220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923005220/0001437749-23-005220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923005220/pbyi20230222_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T14:45:18.657253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9da498bade00ebffe24f099d168c493c3c3ac696","claim":"PUMA BIOTECHNOLOGY, INC. reported the fourth quarter and fiscal year ended December 31, 2022 results: revenue $53.7 million, net income net loss of $5.6 million, or $0.12 per share.","evidence_excerpt":"year 2021. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net for the fourth quarter of 2022 was $53.7 million, compared to $51.0 million in the fourth quarter of 2021. Product revenue, net for the full year 2022 was $200.0 million, compared to $189.1 million in 2021. Based on accounting","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923005220/0001437749-23-005220-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$53.7 million"},{"label":"Net income","value":"net loss of $5.6 million, or $0.12 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}